Wir sind mit live! Mehr erfahren

Corcept Therapeutics

CORT

Börsenwert 11,9 Mrd. $

110,16 USD

-3,21

2,83 %

Zum Börsenschluss Aktualisiert 16. Okt., 16:00 EDT

Vor Börsenbeginn

Nachbörslich

109,84

-0,32

0,29 %

1 Tag

-2,83 %

5 Tage

-9,14 %

1 Monat

-1,48 %

3 Monate

22,78 %

6 Monate

150,59 %

Seit Jahresbeginn

188,38 %

1 Jahr

38,62 %

5 Jahre

481,01 %

10 Jahre

1.621,25 %

Profil: Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.

Mitarbeiter: 730

Gesundheitswesen Biotechnologie

Nachrichten

Positiv

Neutral

Negativ

Stimmung 3 Monate

Positiv 42,3 %

Neutral 46,2 %

Negativ 11,5 %

Zacks Investment Research

Buy 5 Top-Ranked Non-Tech Nasdaq Stocks to Maximize Q4 Gains

ROST, ROKU, APA, CORT and HALO are five non-tech Nasdaq stocks riding strong growth trends and rising earnings estimates, positioning them for potential gains in Q4.

Buy 5 Top-Ranked Non-Tech Nasdaq Stocks to Maximize Q4 Gains

Zacks Investment Research

3 Low-Beta Defensive Stocks to Buy as Inflation Continues to Surge

As inflation surges on rising energy costs, CAH, UNH and CORT stand out as low-beta healthcare stocks with strong expected earnings growth and defensive appeal.

3 Low-Beta Defensive Stocks to Buy as Inflation Continues to Surge

Why Healthcare Stocks Are Hot When the AI Trade Runs Cold

Healthcare—particularly equipment and services and pharmaceuticals—offers investors diversification from AI, according to one report.

Why Healthcare Stocks Are Hot When the AI Trade Runs Cold

Zacks Investment Research

4 Low-Beta Healthcare Stocks to Buy Amid Fears of Another Rate Hike

ABT, CORT, PGEN and BHC offer low-beta healthcare exposure as rate-hike fears and market volatility persist.

4 Low-Beta Healthcare Stocks to Buy Amid Fears of Another Rate Hike

Corcept Announces Planned Leadership Transition

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced the retirement of Sean Maduck, President of the company's Endocrinology division. Justin Gunn will succeed Mr. Maduck and will fully assume his new responsibilities starting October.

Corcept Announces Planned Leadership Transition

Zacks Investment Research

CHMP Backs CORT's Lifyorli Combo in Platinum-Resistant Ovarian Cancer

Corcept's Lifyorli plus nab-paclitaxel wins a positive CHMP opinion for platinum-resistant ovarian cancer, with an EC decision expected in Q4 2026.

CHMP Backs CORT's Lifyorli Combo in Platinum-Resistant Ovarian Cancer

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined wit.

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)

Zacks Investment Research

Will Korlym Continue to Aid CORT's Growth Through the Rest of 2026?

Corcept's Korlym sales rise 6.2% in H1 2026 as demand grows, while Lifyorli's launch offers a path to diversify revenues.

Will Korlym Continue to Aid CORT's Growth Through the Rest of 2026?

Corcept Grows to Mid-Cap on Institutional Support

Institutions keep buying Corcept Therapeutics Incorporated (CORT) shares in big volumes, sending them up 1,016% since 2017 and on the cusp of joining the S&P MidCap 400 index.

Corcept Grows to Mid-Cap on Institutional Support

Corcept: Not Cheap, But Backed By Real Structural Growth

Corcept Therapeutics is evolving into a multi-engine growth platform, driven by expanding Cushing's and a rapid oncology ramp with Lifyorli. CORT delivered strong 2Q26 results: $256.1M revenue (+32% YoY), $47.6M Lifyorli launch, and maintained profitability despite elevated launch expenses. CATALYST and MOMENTUM studies reveal Cushing's is more prevalent than previously thought, structurally expanding the addressable market and supporting multi-billion-dollar revenue potential.

Corcept: Not Cheap, But Backed By Real Structural Growth

Nachrichtenrankings ansehen

Kursdiagramme mit Lightweight Charts™ umgesetzt